This issue of Clinics in Laboratory Medicine, edited by David M. Dorfman, will cover Flow Cytometry. Topics covered in this issue include: Flow cytometric evaluation of primary immunodeficiencies; Flow cytometry of B cell neoplasms; Flow cytometry of T cell neoplasms; Flow cytometry of acute myeloid leukemias; AML minimal residual disease (MRD) assessment by flow cytometric analysis; Acute lymphoblastic leukemia minimal residual disease (MRD) assessment by flow cytometric analysis; Flow cytometric assessment of myelodysplasia and myeloproliferative neoplasms; Flow cytometry of plasma cell neoplasms, including MRD testing; Paroxysmal nocturnal hemoglobinuria (PNH) assessment by flow cytometric analysis; Mast cell disease assessment by flow cytometric analysis; Flow cytometry in pediatric hematopathology; Clinical applications of mass cytometry; Automated analysis of clinical flow cytometry data; and Cost-effective flow cytometric testing strategies.
Clinics in Laboratory Medicine Flow Cytometry Preface: Clinical Flow Cytometry: State-of-the-Art and New Approaches Flow Cytometry of B-Cell Neoplasms Flow Cytometry of T Cells and T-Cell Neoplasms Acute Myeloid Leukemia Immunophenotyping by Flow Cytometric Analysis B Lymphoblastic Leukemia Minimal Residual Disease Assessment by Flow Cytometric Analysis How Do We Use Multicolor Flow Cytometry to Detect Minimal Residual Disease in Acute Myeloid Leukemia? Flow Cytometric Assessment of Chronic Myeloid Neoplasms Diagnosis of Plasma Cell Dyscrasias and Monitoring of Minimal Residual Disease by Multiparametric Flow Cytometry Paroxysmal Nocturnal Hemoglobinuria Assessment by Flow Cytometric Analysis Mast Cell Disease Assessment by Flow Cytometric Analysis Flow Cytometry in Pediatric Hematopoietic Malignancies Flow Cytometric Evaluation of Primary Immunodeficiencies Cost-effective Flow Cytometry Testing Strategies Automated Analysis of Clinical Flow Cytometry Data: A Chronic Lymphocytic Leukemia Illustration Applications of Mass Cytometry in Clinical Medicine: The Promise and Perils of Clinical CyTOF